EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Immuron's enterprise value is €1.43 Mil.
Immuron's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €2.20 Mil. Therefore, Immuron's EV-to-Revenue for today is 0.65.
The historical rank and industry rank for Immuron's EV-to-Revenue or its related term are showing as below:
FRA:ANWA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -39.69 Med: 13.39 Max: 70.84
Current: 0.62
During the past 9 years, the highest EV-to-Revenue of Immuron was 70.84. The lowest was -39.69. And the median was 13.39.
FRA:ANWA's EV-to-Revenue is ranked better than 90.12% of 1043
companies
in the Biotechnology industry
Industry Median: 8.21
vs FRA:ANWA: 0.62
As of today (2024-05-21), Immuron's stock price is €2.00.
Immuron's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.39. Therefore, Immuron's PS Ratio for today is 5.17.
Immuron EV-to-Revenue Historical Data
The historical data trend for Immuron's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immuron's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Immuron's EV-to-Revenue falls into.
Immuron's current Enterprise Value is €1.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immuron's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €2.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron's share price for today is €2.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €0.39.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Immuron's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:ANWA has been successfully added to your 